HeartCare combines two measures in a personalized risk report for a more comprehensive assessment.¹, ², ³
HeartCare is the only test that provides a comprehensive view of rejection
HeartCare is the only test that provides a Personalized Risk Report, combining measures of immune activation and graft injury for more precise risk assessment.
Widely trusted across heart transplant programs
HeartCare is widely used across U.S. heart transplant programs and supported by clinical evidence demonstrating excellent survival rates in monitored patients.³
Transplant centers in the U.S. use HeartCare
New ISHLT guidelines support use of CareDx’s HeartCare solutions, AlloMap and AlloSure, in routine transplant monitoring of heart transplant patients
Resources
Incorporating HeartCare into your workflow
How to Order HeartCare
Find the steps needed to place an order, with ordering options that fit your center.
Interpretation Guides
Access practical guidance for understanding and interpreting results.
Downloads
Webinars
Events
Teuteberg J, Patel S, Baran DA, et al. Multimodal molecular testing provides prognostic value for heart transplant recipients. J Heart Lung Transplant. Published online November 24, 2025. doi:10.1016/j.healun.2025.11.013
Moayedi Y, Teuteberg JJ. Rejection surveillance after heart transplantation: Is paired noninvasive testing the new gold standard? Transplantation. 2025;109(2):285-291.
Khush K, Hall S, Kao A, et al. Surveillance with dual noninvasive testing for acute cellular rejection after heart transplantation: outcomes from the Surveillance HeartCare Outcomes Registry. J Heart Lung Transplant. 2024;43(9):1409-1421.